Anti-Cisplatin modified DNA抗体[CP9/19] (ab103261)

概述

  • 产品名称
    Anti-Cisplatin modified DNA抗体[CP9/19]
  • 描述
    大鼠单克隆抗体[CP9/19] to Cisplatin modified DNA
  • 宿主
    Rat
  • 经测试应用
    适用于: ELISA, Flow Cyt, Dot blotmore details
  • 种属反应性
    与反应: Human
  • 免疫原

    Cisplatin Modified Native DNA.

  • 阳性对照
    • RNA/DNA.
  • 常规说明


    This antibody enables the quantification of cisplatin-induced adducts on DNA. It has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.

性能

  • 形式
    Liquid
  • 存放说明
    Shipped at 4°C. Upon delivery aliquot and store at -20°C. Avoid repeated freeze / thaw cycles.
  • 存储溶液
    Preservative: None
    Constituents: PBS
  • Concentration information loading...
  • 纯度
    Protein A/G purified
  • Primary antibody说明
    This antibody enables the quantification of cisplatin-induced adducts on DNA. It has also been recently used for isolation of DNA fragments carrying adducts to enhance the sensitivity of subsequent PCR-based analyses and is central to ongoing studies of variation in the nature of cisplatin adducts formed in different cell lines.
  • 克隆
    单克隆
  • 克隆编号
    CP9/19
  • 骨髓瘤
    Y3/Ag1.2.3
  • 同种型
    IgG2a
  • 研究领域

应用

Our Abpromise guarantee covers the use of ab103261 in the following tested applications.

The application notes include recommended starting dilutions; optimal dilutions/concentrations should be determined by the end user.

应用 Ab评论 说明
ELISA Use at an assay dependent concentration.
Flow Cyt Use at an assay dependent concentration. PubMed: 23370278

ab18450 - Rat IgG2a kappa monoclonal, is suitable for use as an isotype control with this antibody.

Dot blot Use at an assay dependent concentration. PubMed: 25356874

图片

  • ab103261 staining Cisplatin modified DNA in human ovarian cancer cell line A2780 by Flow Cytometry. Cells in culture were detached by accutase treatment, fixed with 70% ehtanol for 30 min at 4°C and permeabilized with 100ug/ml digitonin in PBS. The sample was incubated with the primary antibody (1/200 in PBS + 1% FBS) for 18 hours at 4°C. A FITC-conjugated rabbit anti-rat IgG H&L polyclonal (1/200) was used as the secondary antibody. Gating Strategy: FITC positive cells.

    The sh2 represents the gene knock down cell line which showed positive staining with anti-cisplatin adduct antibody upon cisplatin treatment, whereas the control cells (cis-R, resistant to cisplatin) did not show any staining with anti-cis adduct antibody upon cisplatin treatment.

    See Abreview

文献

This product has been referenced in:
  • Shi Q  et al. The identification of the ATR inhibitor VE-822 as a therapeutic strategy for enhancing cisplatin chemosensitivity in esophageal squamous cell carcinoma. Cancer Lett 432:56-68 (2018). Read more (PubMed: 29890208) »
  • Zhang M  et al. Nanoparticle co-delivery of wortmannin and cisplatin synergistically enhances chemoradiotherapy and reverses platinum resistance in ovarian cancer models. Biomaterials 169:1-10 (2018). ICC/IF . Read more (PubMed: 29631163) »

See all 11 Publications for this product

客户评价及客户问答

Filter by Application

Filter by Species

Filter by Ratings

Application
Flow Cytometry
Sample
Human Cell (human ovarian cancer cell line A2780)
Permeabilization
Yes - 100ug/ml digitonin in PBS
Gating Strategy
FITC positive cells
Specification
human ovarian cancer cell line A2780
Preparation
Cell harvesting/tissue preparation method: Cells in culture detached by accutase treatment
Sample buffer: PBS
Fixation
70% ehtanol for 30 min at 4 degrees
Username

Abcam user community

Verified customer

提交于 Apr 16 2015

Application
Immunocytochemistry/ Immunofluorescence
Sample
Human Cell (ovarian cancer A2780 cell line)
Specification
ovarian cancer A2780 cell line
Permeabilization
Yes - 0.1% digitonin in PBS
Fixative
70% ethanol
Username

Abcam user community

Verified customer

提交于 Aug 25 2014

Application
ELISA
Sample
Human Cell (melanoma)
Specification
melanoma
Blocking step
BSA as blocking agent for 1 hour(s) and 0 minute(s) · Concentration: 0.74µg/mL · Temperature: 20°C
Type
Direct
Username

Abcam user community

Verified customer

提交于 May 04 2012

Please note: All products are "FOR RESEARCH USE ONLY AND ARE NOT INTENDED FOR DIAGNOSTIC OR THERAPEUTIC USE"

注册